India: Clarifying The Patent Process

Last Updated: 5 January 2016
Article by Rishu Srivastava

Most Read Contributor in India, September 2018

The patent system is imperative to fostering invention, innovation and for socio-economic growth of the nation. From being wielded as a defensive asset, to becoming a lynchpin in the intellectual property portfolio of an entity, patents have weaved into every facet of an organisation's strategic plan and economic policy.

This sentiment is echoed by various governmental policies and guidelines that underscore initiatives to stimulate the development of effective IP infrastructure that engenders consistent investment in R&D. Espousal of the reforms brought out by such guidelines and policies, when set against the backdrop of performance of key innovation sectors, highlight the significant role that it has played in the sustainable growth of the industry.

In conformity with the public policy objectives of the Patent Act, the Indian Patent Office has issued guidelines for processing patent applications relating to traditional knowledge and biological material, and biotechnology, and as well as draft guidelines for applications relating to pharmaceutical patent applications.

These guidelines intend to establish uniform and consistent practices in the examination of patent applications of these allied subjects under the Patent Act 1970, by assisting examiners and controllers of the patent office by removing ambiguity and by clarifying the extent to which such applications had to be dealt under various provisions of the Patents Act.

The guidelines for the examination of pharmaceutical patents incorporate analysis of the courts, with the objective of helping to improve the examination standard and introduce harmonious practice among the technical officers of the system.

For examination of Markush claims

The guidelines directs examiners to raise objection under 'unity of invention' and insufficiency of the disclosure if while examining Markush claims any one of the following criteria is not met: whether the complete specification: (i) discloses all the possible embodiments covered under the claimed Markush formula; (ii) such embodiments share a common use or property; (iii) such possible embodiments share common structure; (iv) physical and chemical properties of claimed compound are disclosed; (v) test conducted for each embodiment is provided; (vi) at least one process for preparing the compounds is disclosed when more than one processes are claimed.

It would, however, be challenging for the applicant to conduct and do define all embodiments of the Markush formula, especially for a chemical structure with plurality of functionally equivalent chemical groups in one or more parts of the compound.

For prior art search

Examiners are directed to frame search strategies by combining parameters including keywords, compound searches, and so on, when conducting prior art searches. The guidelines also suggest using methods such as: molecular formula and structural formula searching; generic name searching (INN); and using International Patent Classification (IPC) for searching and identifying compounds.

Examiners are also directed to ask the applicant to disclose the INN of those pharmaceutical compounds where it is found that the applicant is claiming the second use/indication of an already known pharmaceutical compound.

Assessment of invention

The draft guidelines give explicit explanation and examples regarding the assessment of novelty, inventive step and obviousness of the chemical compound. It specifically prohibits consideration of the following types of claims, stating that they neither pertain to a product or a process: use of compounds in the treatment of; the process of preparing; in the composition of; and a product of a known substance for the treatment of new disease (which is nothing but a use/application claim).

Assessment of novelty

In addition to defining with examples the relevant sections of the Patent Act, with respect to 'new invention', 'priority date' and inherent anticipation, the guidelines specify implicit disclosure, stating that if the prior art discloses the claimed subject matter in such an implicit manner that it leaves no doubt in the mind of examiner as to the content of the prior art and the practical effect of its teaching, an objection regarding lack of novelty should be raised. It is further stated that the question of implicit disclosure is often a mixed issue of novelty and inventive step.

The draft guidelines also say that claims of combinations of pharmaceutical products should be dealt with under novelty as well, as quite often they escape the question of novelty and are dealt under the inventive step or relevant clauses of Section 3 of the act.

With respect to product-by-process claims, it is noted that they must also define a novel and unobvious product, and that its patentability cannot depend on the novelty and unobviousness of the process limitations alone, ie, the product must qualify for novelty and inventive step irrespective of the novelty or inventive step of the process.

Assessment of inventive step

The draft guidelines state that a surprising effect or synergistic outcome of combinations, prior art prejudice, and so on usually demonstrates the non-obvious nature of the invention. But it is clarified that enhanced effects cannot be cited as evidence of inventive step if they emerge from obvious tests.

In order to aid an examiner with objectively analysing inventive step, the following steps have been provided:

  • Identify the inventive concept of the claim in question;
  • Identify the 'person skilled in the art';
  • Identify the relevant common general knowledge of the person skilled in the art at the priority date;
  • Identify what, if any, differences exist between the matter cited as forming part of the state of the art and the inventive concept of the claim; and
  • Viewed without any knowledge of the alleged invention as claimed, do those differences constitute steps that would have been obvious to the person skilled in the art or do they require any degree of inventive ingenuity?

The draft guidelines also elaborate the assessment of industrial applicability and the inventions that are not patentable under a provision of Section 3 of the Patent Act. Section 3(d) deserves special attention in the context of pharmaceutical inventions as it stipulates that an incremental invention, based on an already known substance, having established medicinal activity, will be treated as a same substance, and will fall foul of patentability, if the invention in question fails to demonstrate significantly improved therapeutic efficacy with respect to that known compound.

The guidelines reiterate comments in Novartis AG V Union of India (UOI) and Ors, stating that the Section 3(d) sets up a second tier of qualifying standards for chemical substances/ pharmaceutical products in order to leave the door open for true and genuine inventions but, at the same time, to check any attempt at repetitive patenting or extension of the patent term on spurious grounds.

The guidelines further clarify that in the context of pharmaceutical patenting, the 'efficacy' should be understood as 'therapeutic efficacy'. While defining 'new product' in the context of Section 3(d), it is clarified that the test does not bar patent protection for all incremental inventions of chemical and pharmaceutical substances.

Sufficiency of description, clarity and support of the claims

The draft guidelines specify that while assessing the sufficiency of disclosure, nondisclosure of the source and geographical origin of the biological materials used in the invention should be treated as insufficiency of disclosure. It is further directed that if the declaration in a patent application for biological material from India is cancelled by the applicant, and the specification also states that the source and geographical origin of the biological material is not from India, the specification should be amended by including a separate heading/paragraph at the beginning of the description that the biological material used in the invention is not from India and should specify the country of source and origin.

It is also clarified that when claims seek to protect things that are not identified by the applicant at the time of filing the application, but that may be identified in the future by carrying out the applicant's process, such claims are not patentable on the ground of insufficiency of description.

The draft guidelines further direct examiners that while assessing the sufficiency of disclosure, it must be ensured that the best method for performing the invention is described so that the subject matter that is claimed, and not only a part of it, must be capable of being carried out by a skilled person in the relevant art without the burden of an undue amount of experimentation or application of inventive ingenuity.

If an application claims substance, composition or combination, a detailed report on the test conducted and experimental results with inference of such a test is required to be provided in the description. Test parameters, choice of testing method, mode of drug delivery, results obtained with explanation and inference, should also be provided in the specification.

The issuance of guidelines for examination of patent applications in the field of pharmaceuticals is certainly a positive step, taking into consideration that almost 25 percent of applications filed in India in 2012 to 2013 were in the field of drugs, chemicals and biotechnology. Similarly, 43 percent of the total patents granted were from these allied fields, clearly reflecting that pharmaceutical patenting is an extremely important aspect of India's patent system.

These guidelines will not only assist examiners but also applicants as to how the specification should be drafted and how to overcome the objections raised by the patent office.

This shall be more pronounced in the case of foreign applicants, as not only are the majority of patent applications filed by foreign entities in India, they do not have limitations and requirements as imposed by Section 3(d) of the Patent Act.

All the interlocking variables covered in the guidelines will encourage both national and international entities to effectively prosecute their patent applications in India.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Vaish Associates Advocates
Intepat IP Services Pvt Ltd
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Vaish Associates Advocates
Intepat IP Services Pvt Ltd
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions